Every research field has its reference compound, the one everything else gets measured against. In incretin research that compound is semaglutide. It has the largest published footprint of any peptide in this catalog, and when a study compares a new metabolic candidate against an established baseline, semaglutide is usually the baseline.
What semaglutide is
Semaglutide is a synthetic peptide described in the literature as a glucagon-like peptide-1 (GLP-1) receptor agonist: one molecule, one receptor target, at the center of incretin signaling. Structural modifications against the native GLP-1 sequence give it the long half-life that made the molecule practical to study and develop, a story told across a substantial body of published pharmacology work.
Where the evidence stands
Pharmaceutical forms of semaglutide are approved drugs, developed through some of the most cited clinical programs in modern metabolic medicine. That mountain of published human data is precisely what makes the molecule so useful as a research reference: its receptor pharmacology is thoroughly characterized, and new incretin compounds are routinely benchmarked against it.
As always: research-grade semaglutide is a laboratory material, not a pharmaceutical product. It is not manufactured or regulated as a drug and is sold strictly for laboratory and in-vitro research.
What laboratories study
Published laboratory work involving semaglutide spans GLP-1 receptor binding and signaling, comparative studies against dual and triple agonists like tirzepatide and retatrutide, and analytical chemistry, where it serves as a well-characterized reference for chromatography and mass spectrometry methods.
In our catalog
We stock Semaglutide (10mg) as a lyophilized research compound with its CAS number, molecular formula, and molecular weight on the product page, and a printed lot number on every vial tied to our public COA ledger. Lots awaiting certification are labeled pending.
Quick answers
Why is semaglutide the reference incretin? Because its pharmacology is the most thoroughly documented in the class, which makes it the natural comparison point in published studies.
How does it differ from tirzepatide and retatrutide? Semaglutide targets one receptor (GLP-1); tirzepatide adds GIP; retatrutide adds GIP and glucagon.
How do I verify a lot? Match the lot number on the label to its ledger entry.
For laboratory and in-vitro research use only.
For laboratory and in-vitro research use only. Not for human or veterinary use. See our research-use disclaimer.
